Mezquita-Raya P, Darbà J, Ascanio M, Ramírez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus – from the Spanish National Health System perspective. Expert Rev Pharmacoecon Outcomes Res. Available from: https://doi.org/10.1080/14737167.2017.1345628
When the above article was first published online, the below paragraph in section “2.2.1. Clinical data” was included in error. This paragraph has now been removed.
“To obtain the corresponding IDeg basal dose for T1DM B/B patients, the calculation was as follows: (1) the IGlar basal dose for T1DM B/B patients was 33.10 units/day; (2) the IDeg/IGlar basal dose ratio was 0.87; (3) the IDeg basal dose for T1DM B/B patients was 33.10 × 0.87 = 28.80 units/day. In patients with T2DM treated with B/B and BOT insulin, the estimation of IGlar OD was based on a randomized, 52-week, treat to-target trial comparing insulin detemir (IDet) with insulin IGlar by Rosenstock et al. [25]. After 52 weeks, the OD dose of IDet (n = 102) was 0.52 units/kg. Therefore, dose IDet (one injection) was 51.70 units/day. The mean dosage to achieve glucose goal was the same with both insulins: IDet and IGlar for which similar calculations applied to IGlar as for IDet [26]. Based on that, the corresponding doses for IGlar OD in T2DM patients treated with B/B and BOT insulin were 66.60 and 51.70 units/day, respectively (Table 1).”
The authors apologise for this error.